In concordance with previously reported observations that (i) a rare haplotype in the ARRDC3 locus is linked to male obesity in humans, (ii) global KO of ARRDC3 in mice protects them against age-induced obesity, insulin resistance, and hepatic steatosis, and (iii) ARRDC3 seems to be involved in modulation of adipose tissue functioning through the regulation of β-adrenergic signaling [126], the presented findings suggest that ARRDC3 may be a promising target for obesity and/or diabetes treatment. Here, ARRDC3 is linked to fatty liver disease.